+33 33 0
Published 4 years ago by kxh with 1 Comments
by kxh
4 years ago 1

Big pharma can only see the benefit of R&D for wealthy markets

There is too little incentive for pharmaceutical companies to work on treatments for diseases of low-income countries

Continue Reading https://www.theguardian.com

Join the Discussion

  • Auto Tier
  • All
  • 1
  • 2
  • 3
Post Comment
  • Gozzin
    +6

    Yep,if they can't line their pockets really fast they won't bother,just let um die.

    4 years ago
    Reply
    Save

Here are some other snaps you may like...

discover your
interests.

Check out our front page for a lot more stuff!

With no prospects for profits, big pharma neglects new infectious diseases

Removing the Profit From Our Pills: The Case for a Public Pharma System

There's a Big Problem With Making Vaccines Mandatory, And It's Worth Paying Attention

Medicine needs to embrace open source

Dodgy treatment: it's not us, it's the other lot, say the experts. So who do we believe?